News

A groundbreaking study, led by Mikhail Kosiborod, MD, vice president of research at Saint Luke's Health System, has been named the scientific breakthrough of the year by Science Magazine.

TAVR in asymptomatic and minimally symptomatic patients is associated with a high survival rate, but relatively minor improvements, according to new research.

AARP talked to Dr. James O'Keefe about the benefits of omega fatty acids and how much you should be consuming.

A growing body of evidence correlates shorter running sessions to significant health benefits, especially those regarding longevity and mental health.

A man from Columbia, Missouri, got a new heart and a second chance at life, marking the 1,000th heart transplant at Saint Luke's Mid America Heart Institute.

Dr. Timothy Bateman spoke with Cardiovascular Business about his group's findings and what it is like to work with flurpiridaz.

In the past, many women born with a heart condition were told they would not be able to birth children safely.

The study shows that the diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial.

Semaglutide, the active ingredient on weight loss drugs Wegovy and Ozempic, shows evidence that the drug may also help reduce the risks of heart disease.

The diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial.